Elinzanetant Effectively Reduces Vasomotor Symptoms in Breast Cancer Patients on Endocrine Therapy
A new phase 3 trial shows that elinzanetant significantly reduces hot flashes and night sweats in women undergoing endocrine therapy for breast cancer, improving quality of life.
A recent phase 3 clinical trial has demonstrated that elinzanetant, a neurokinin receptor-targeted medication, significantly decreases vasomotor symptoms such as hot flashes and night sweats in women undergoing endocrine therapy for hormone receptor-positive breast cancer. Published online on June 2, 2025, in the New England Journal of Medicine, the study was presented during the American Society of Clinical Oncology annual meeting held from May 31 to June 4 in Chicago.
The research was led by Dr. Fatima Cardoso from the Champalimaud Foundation in Lisbon, Portugal. It involved women aged 18 to 70 experiencing moderate-to-severe vasomotor symptoms linked to endocrine therapy either for breast cancer treatment or prevention. Participants were randomly assigned to receive daily doses of 120 mg of elinzanetant for 52 weeks or a placebo for the initial 12 weeks, followed by elinzanetant for 40 weeks. A total of 474 women participated, with only one using endocrine therapy for breast cancer prevention.
Results showed that women treated with elinzanetant had a greater reduction in vasomotor symptom frequency. At week 4, the average decline was 6.5 episodes per day compared to 3.0 episodes in the placebo group. By week 12, the reductions were 7.8 and 4.2 episodes, respectively. The study also noted that about 70% of women on elinzanetant experienced at least one adverse event, with serious adverse events occurring in 2.5% versus 0.6% in the placebo group. Despite this, the drug's benefits in alleviating symptoms and improving quality of life were deemed significant.
The authors highlighted that these findings are consistent with previous research in postmenopausal women, suggesting elinzanetant as a promising therapy for managing vasomotor symptoms. Certain authors disclosed financial ties to Bayer, the pharmaceutical company developing elinzanetant, which funded the study.
This innovative treatment offers hope for women suffering from menopause-like symptoms caused by cancer treatments, providing a new pathway to improve comfort and overall health during breast cancer management.
Source: https://medicalxpress.com/news/2025-06-elinzanetant-vasomotor-symptoms-women-breast.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Privacy Risks of Menstrual Tracking Apps Highlight Need for Better Data Protection
Menstrual tracking apps collect sensitive personal data, presenting significant privacy and safety risks. Experts call for better regulation and public health alternatives to protect users and ensure data is used ethically.
Chagas Disease Now Established in California and the Southern United States
Chagas disease, caused by the Trypanosoma cruzi parasite and transmitted by kissing bugs, is now an established health concern in California and the southern United States, with potential underdiagnosis and local transmission.
Pre-IVF Weight Loss Support Can Enhance Pregnancy Success and Reduce Treatment Needs
Supporting women with obesity through weight loss programs before IVF can boost pregnancy rates, potentially reduce treatment needs, and promote fairer access to fertility care. Recent studies emphasize the importance of preconception weight management for improved reproductive success.
Understanding Persistent Regional Disparities in Opioid Overdose Deaths Despite Overall Decline
Despite a decline in national opioid overdose death rates, regional disparities in the US persist, with the western states experiencing a rise driven by fentanyl and stimulant co-involvement. This study emphasizes the need for targeted, region-specific strategies to combat the evolving opioid crisis.